AbbVie to buy drug developer Cerevel for $8.7 billion
(Reuters) – AbbVie (NYSE:ABBV) said on Wednesday it would buy Cerevel Therapeutics, a developer of drugs for neurological conditions, for…
(Reuters) – AbbVie (NYSE:ABBV) said on Wednesday it would buy Cerevel Therapeutics, a developer of drugs for neurological conditions, for…
(Reuters) – Trading app operator Robinhood Markets Inc (NASDAQ:HOOD) said on Thursday it has launched commission-free crypto trading to customers…
(Reuters) – EU lawmakers and governments were still wrangling on Thursday over several key issues on landmark rules governing artificial…
(Reuters) – Thailand’s Prime Minister Srettha Thavisin on Thursday said he showed Tesla (NASDAQ:TSLA) executives around industrial estates in the…
(Reuters) – The UK’s FTSE 100 fell in broad-based declines on Thursday as a strengthening pound weighed on the exporter-heavy…
(Reuters) – A top U.S. banking regulator on Wednesday warned banks to manage the risks to consumers posed by increasingly…
(Reuters) – Unidentified governments are surveilling smartphone users via their apps’ push notifications, a U.S. senator warned on Wednesday. In…
Mizuho raised its price targets for Micron Technology (NASDAQ:MU) and Western Digital (NASDAQ:WDC) in a note Wednesday, stating they continue…
(Reuters) – A fall in the price of cobalt, a silvery-blue metal used in electric vehicle (EV) batteries, electronics and…
(Reuters) – Exxon Mobil will target annual project spending of between $22 billion and $27 billion through 2027, the company…